Clinical trial
The Efficacy and Safety of VA Alternating With Low-dose CHA in the Treatment of Newly Diagnosed Unfit AML: a Prospective, Multi-centers, Single Arm Phase II Study
NCT07172204 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of VA Alternating With Low-dose CHA in the Treatment of Newly Diagnosed Unfit AML: a Prospective, Multi-centers, Single Arm Phase II Study
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 16, 2025
- Completion date
- July 31, 2029
- Enrollment
- 25 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
age ≥60, intensive chemotherapy unfit, newly diagnosed acute myeloid leukemia (aml)